$5M grant expands entrepreneurship opportunities at UH

coming soon

Known as the Wayne B. Duddlesten Free Enterprise Institute, the new program will operate in association with the UH Bauer College’s Cyvia and Melvyn Wolff Center for Entrepreneurship and be open to all UH students. Photo via bauerticker.uh.edu

A $5 million gift from the Wayne Duddlesten Foundation will establish expanded opportunities for entrepreneurship at the University of Houston, according to an announcement from the college earlier this month.

Known as the Wayne B. Duddlesten Free Enterprise Institute, the new program will operate in association with the UH Bauer College’s Cyvia and Melvyn Wolff Center for Entrepreneurship and be open to all UH students. It's expected to launch in 2024.

UH staff from the Duddlesten Institute and the Wolff Center will be able match budding entrepreneurs across campus with mentors, offer website-building resources, provide legal services and other tools.

"Our goal is to empower imaginative thinkers from idea to market," Paul A. Pavlou, dean of the Bauer College of Business and Cullen Distinguished Chair Professor, said in a statement. "We will support the process from a concept to incubation and continue offering necessary resources all the way to launching a successful new business.”

Dave Cook, executive director of the Wolff Center, said the new institute will create a new type of "synergy across campus."

"It will help create a fabric of innovation, talent, financial, legal and technical service along with a commitment to long held values of the importance of character and integrity as businesses are created," Cook said. "We are honored to share this vision through this collaboration.”

Duddlesten has been a longtime supporter of the university. The successful real estate developer, who's credited for bringing the Rockets to Houston in the '70s, was a Houston native and UH graduate.

His foundation donated $5 million to establish an endowed scholarship at Bauer for students studying entrepreneurship or real estate in 2020. It also established an endowed Tier One Scholarship and endowed scholarship in the Graduate College of Social Work, as well as 25 one-time scholarships for Wolff Center students over the years.

Duddlesten also served as a trustee emeritus and advisory board member for the UH Foundation and the UH System Development Board before his death in 2010.


Earlier this academic year, Rice University also unveiled a new facility dedicated to Ralph O'Connor, former president and CEO of the Highland Oil Company and founder of Ralph S. O’Connor & Associates. The $152 million, state-of-the-art facility features five floors of labs, classrooms and seminar rooms, and is Rice's largest core campus research facility. Click here to read more.
From Your Site Articles
A new program launched by two UH-based organizations will help early-stage startups commercialize, apply for grants, and more. Photo via UH.edu

University of Houston launches new collaborative program for startups in Houston, Gulf Coast Region

ready to grow

Two University of Houston organizations have partnered up to further support early-stage startups in the Gulf Coast Region.

The university announced this month that its UH Technology Bridge and the UH Texas Gulf Coast Small Business Development Center are now accepting applications for a new, collaborative program that will help innovators and entrepreneurs develop a pitch or commercialization plan. The program will also guide participants in applying for Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) grants and other investments.

Applications are open to those with the university and across the region.

"We are excited to partner with the University of Houston Technology Bridge to provide this valuable support to early-tech startups in the Texas Gulf Coast region," Steven Lawrence, director of the UH Texas Gulf Coast SBDC Network, says in a statement. "Our program is designed to help innovators take their ideas to the next level and prepare for success in the marketplace."

"Our goal is to help innovators turn their ideas into successful businesses, and this partnership will help us achieve that goal," Tanu Chatterji, Associate Director of Startup Development at UH, echoes in the news release.

The UH Texas Gulf Coast SBDC Network is one of 14 SBDCs in the Texas Gulf Coast Region that's part of UH's C.T. Bauer College of Business and funded in part by the U.S. Small Business Administration. The centers provide no-cost and affordable business training and advising.

The UH Tech Bridge focuses on providing research and development space to UH-affiliated startups and entrepreneurs. The 15-building complex and its 31,000 square feet of incubator space houses more than 20 small companies and startups that provide internship and learning opportunities for UH students, along with several federally funded research centers and institutes.

Earlier this year, the Tech Bridge received a $2.875 million grant from the U.S. Department of Housing and Urban Development. The grant is slated to benefit the UH Industry & International Innovation Hub and will establish The Deck Innovation & Coworking Center.

Ramanan Krishnamoorti, the vice president of energy and innovation at the University of Houston who oversees the UH Technology Bridge, spoke with the Houston Innovators Podcast earlier this summer about UH's plans to build a central campus hub for innovation and the need to encourage more innovation and entrepreneurship.
Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Property Showcase

Greentown Labs names Lawson Gow as its new Houston leader

head of hou

Greentown Labs has named Lawson Gow as its Head of Houston.

Gow is the founder of The Cannon, a coworking space with seven locations in the Houston area, with additional partner spaces. He also recently served as managing partner at Houston-based investment and advisory firm Helium Capital. Gow is the son of David Gow, founder of Energy Capital's parent company, Gow Media.

According to Greentown, Gow will "enhance the founder experience, cultivate strategic partnerships, and accelerate climatetech solutions" in his new role.

“I couldn’t be more excited to join Greentown at this critical moment for the energy transition,” Gow said in a news release. “Greentown has a fantastic track record of supporting entrepreneurs in Houston, Boston, and beyond, and I am eager to keep advancing our mission in the energy transition capital of the world.”

Gow has also held analyst, strategy and advising roles since graduating from Rice University.

“We are thrilled to welcome Lawson to our leadership team,” Georgina Campbell Flatter, CEO of Greentown Labs, added in the release. “Lawson has spent his career building community and championing entrepreneurs, and we look forward to him deepening Greentown’s support of climate and energy startups as our Head of Houston.”

Gow is the latest addition to a series of new hires at Greentown Labs following a leadership shakeup.

Flatter was named as the organization's new CEO in February, replacing Kevin Dutt, Greentown’s interim CEO, who replaced Kevin Knobloch after he announced that he would step down in July 2024 after less than a year in the role.

Greentown also named Naheed Malik its new CFO in January.

Timmeko Moore Love was named the first Houston general manager and senior vice president of Greentown Labs. According to LinkedIn, she left the role in January.

---

This article originally appeared on our sister site, EnergyCapitalHTX.com.

Houston foundation grants $27M to support Texas chemistry research

fresh funding

Houston-based The Welch Foundation has doled out $27 million in its latest round of grants for chemical research, equipment and postdoctoral fellowships.

According to a June announcement, $25.5 million was allocated for the foundation's longstanding research grants, which provide $100,000 per year in funding for three years to full-time, regular tenure or tenure-track faculty members in Texas. The foundation made 85 grants to faculty at 16 Texas institutions for 2025, including:

  • Michael I. Jacobs, assistant professor in the chemistry and biochemistry department at Texas State University, who is investigating the structure and thermodynamics of intrinsically disordered proteins, which could "reveal clues about how life began," according to the foundation.
  • Kendra K. Frederick, assistant professor in the biophysics department at The University of Texas Southwestern Medical Center, who is studying a protein linked to Parkinson’s disease.
  • Jennifer S. Brodbelt, professor in chemistry at The University of Texas at Austin, who is testing a theory called full replica symmetry breaking (fullRSB) on glass-like materials, which has implications for complex systems in physics, chemistry and biology.

Additional funding will be allocated to the Welch Postdoctoral Fellows of the Life Sciences Research Foundation. The program provides three-year fellowships to recent PhD graduates to support clinical research careers in Texas. Two fellows from Rice University and Baylor University will receive $100,000 annually for three years.

The Welch Foundation also issued $975,000 through its equipment grant program to 13 institutions to help them develop "richer laboratory experience(s)." The universities matched funds of $352,346.

Since 1954, the Welch Foundation has contributed over $1.1 billion for Texas-nurtured advancements in chemistry through research grants, endowed chairs and other chemistry-related ventures. Last year, the foundation granted more than $40.5 million in academic research grants, equipment grants and fellowships.

“Through funding basic chemical research, we are actively investing in the future of humankind,” Adam Kuspa, president of The Welch Foundation, said the news release. “We are proud to support so many talented researchers across Texas and continue to be inspired by the important work they complete every day.”

New Houston biotech co. developing capsules for hard-to-treat tumors

biotech breakthroughs

Houston company Sentinel BioTherapeutics has made promising headway in cancer immunotherapy for patients who don’t respond positively to more traditional treatments. New biotech venture creation studio RBL LLC (pronounced “rebel”) recently debuted the company at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.

Rima Chakrabarti is a neurologist by training. Though she says she’s “passionate about treating the brain,” her greatest fervor currently lies in leading Sentinel as its CEO. Sentinel is RBL’s first clinical venture, and Chakrabarti also serves as cofounder and managing partner of the venture studio.

The team sees an opportunity to use cytokine interleukin-2 (IL-2) capsules to fight many solid tumors for which immunotherapy hasn't been effective in the past. “We plan to develop a pipeline of drugs that way,” Chakrabarti says.

This may all sound brand-new, but Sentinel’s research goes back years to the work of Omid Veiseh, director of the Rice Biotechnology Launch Pad (RBLP). Through another, now-defunct company called Avenge Bio, Veiseh and Paul Wotton — also with RBLP and now RBL’s CEO and chairman of Sentinel — invested close to $45 million in capital toward their promising discovery.

From preclinical data on studies in mice, Avenge was able to manufacture its platform focused on ovarian cancer treatments and test it on 14 human patients. “That's essentially opened the door to understanding the clinical efficacy of this drug as well as it's brought this to the attention of the FDA, such that now we're able to continue that conversation,” says Chakrabarti. She emphasizes the point that Avenge’s demise was not due to the science, but to the company's unsuccessful outsourcing to a Massachusetts management team.

“They hadn't analyzed a lot of the data that we got access to upon the acquisition,” explains Chakrabarti. “When we analyzed the data, we saw this dose-dependent immune activation, very specific upregulation of checkpoints on T cells. We came to understand how effective this agent could be as an immune priming agent in a way that Avenge Bio hadn't been developing this drug.”

Chakrabarti says that Sentinel’s phase II trials are coming soon. They’ll continue their previous work with ovarian cancer, but Chakrabarti says that she also believes that the IL-2 capsules will be effective in the treatment of endometrial cancer. There’s also potential for people with other cancers located in the peritoneal cavity, such as colorectal cancer, gastrointestinal cancer and even primary peritoneal carcinomatosis.

“We're delivering these capsules into the peritoneal cavity and seeing both the safety as well as the immune activation,” Chakrabarti says. “We're seeing that up-regulation of the checkpoint that I mentioned. We're seeing a strong safety signal. This drug was very well-tolerated by patients where IL-2 has always had a challenge in being a well-tolerated drug.”

When phase II will take place is up to the success of Sentinel’s fundraising push. What we do know is that it will be led by Amir Jazaeri at MD Anderson Cancer Center. Part of the goal this summer is also to create an automated cell manufacturing process and prove that Sentinel can store its product long-term.

“This isn’t just another cell therapy,” Chakrabarti says.

"Sentinel's cytokine factory platform is the breakthrough technology that we believe has the potential to define the next era of cancer treatment," adds Wotton.

View All Listings